FY2030 Earnings Estimate for Absci Issued By HC Wainwright

Absci Corporation (NASDAQ:ABSI) – HC Wainwright issued their FY2030 EPS estimates for Absci in a note issued to investors on Wednesday, March 25th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings of $0.61 per share for the year. HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Absci’s current full-year earnings is ($0.89) per share.

Several other research analysts have also issued reports on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $7.00 target price on shares of Absci in a research report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Absci in a report on Wednesday, January 21st. Finally, Morgan Stanley lowered Absci from an “overweight” rating to an “equal weight” rating and set a $4.32 price target on the stock. in a research note on Thursday, January 8th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $7.08.

Absci Price Performance

Absci stock opened at $2.88 on Thursday. Absci has a 1-year low of $2.01 and a 1-year high of $5.23. The business has a fifty day moving average price of $2.77 and a 200-day moving average price of $3.21. The stock has a market capitalization of $440.70 million, a price-to-earnings ratio of -3.39 and a beta of 2.12.

Absci (NASDAQ:ABSI) last issued its quarterly earnings results on Tuesday, March 24th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.07). Absci had a negative return on equity of 62.33% and a negative net margin of 4,113.68%.The business had revenue of $0.65 million for the quarter, compared to analyst estimates of $1.38 million.

Insider Buying and Selling at Absci

In related news, insider Andreas Busch acquired 100,000 shares of the stock in a transaction dated Thursday, March 12th. The stock was acquired at an average cost of $2.29 per share, for a total transaction of $229,000.00. Following the completion of the purchase, the insider owned 421,446 shares of the company’s stock, valued at approximately $965,111.34. This represents a 31.11% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Sean Mcclain sold 26,761 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $2.99, for a total transaction of $80,015.39. Following the sale, the chief executive officer directly owned 8,334,567 shares in the company, valued at $24,920,355.33. This trade represents a 0.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 10.49% of the company’s stock.

Institutional Trading of Absci

Large investors have recently added to or reduced their stakes in the company. Jones Financial Companies Lllp raised its position in Absci by 41.9% during the 3rd quarter. Jones Financial Companies Lllp now owns 12,317 shares of the company’s stock worth $37,000 after buying an additional 3,638 shares during the last quarter. Legal & General Group Plc boosted its holdings in shares of Absci by 45.9% in the 2nd quarter. Legal & General Group Plc now owns 11,690 shares of the company’s stock valued at $30,000 after acquiring an additional 3,678 shares during the last quarter. SG Americas Securities LLC boosted its holdings in shares of Absci by 20.7% in the 3rd quarter. SG Americas Securities LLC now owns 21,882 shares of the company’s stock valued at $67,000 after acquiring an additional 3,758 shares during the last quarter. Deutsche Bank AG increased its stake in shares of Absci by 5.6% in the fourth quarter. Deutsche Bank AG now owns 92,148 shares of the company’s stock worth $322,000 after acquiring an additional 4,892 shares during the period. Finally, BNP Paribas Financial Markets increased its stake in shares of Absci by 91.2% in the second quarter. BNP Paribas Financial Markets now owns 11,287 shares of the company’s stock worth $29,000 after acquiring an additional 5,385 shares during the period. Hedge funds and other institutional investors own 52.05% of the company’s stock.

Absci News Roundup

Here are the key news stories impacting Absci this week:

• Positive Sentiment: HC Wainwright published a long‑range bullish view (FY2030) forecasting EPS of $0.61 and reiterating a “Buy” stance with an $8.00 price objective — a signal of strong upside expectations from a sell‑side shop that can support buying interest.
• Positive Sentiment: Needham & Company reaffirmed its Buy rating and $7.00 price target, reiterating institutional support and another catalyst for upside if the company executes on its pipeline programs. Needham Reaffirmed Buy
• Neutral Sentiment: Management’s Q4 2025 earnings call/transcripts emphasize strategic progress and pipeline advancement (discussion of moves toward ABS‑201 and broader platform work), which underpins long‑term narrative even as near‑term results are mixed. ABSI Q4 2025 Earnings Call Transcript (Yahoo)
• Neutral Sentiment: Full call transcripts are available for investors who want the verbatim management commentary and Q&A to judge execution risk and timelines. ABSI Q4 2025 Earnings Call Transcript (Seeking Alpha)
• Negative Sentiment: Coverage highlights Absci’s cash‑burn profile and runway concerns — analysts and commentaries are watching how quickly R&D spend and program timing will pressure liquidity, which increases downside risk if financing terms or dilution become necessary. Here’s Why We’re Watching Absci’s Cash Burn Situation
• Negative Sentiment: Analyst repositioning: Seeking Alpha reported a downgrade to “Hold” citing that ABS‑101 has been deprioritized while management pivots resources to ABS‑201 — the program shift raises execution and timeline uncertainty, pressuring sentiment. Absci: Downgrade To ‘Hold’
• Negative Sentiment: Recent coverage and pre‑market notes flagged shares moving lower after the quarter; the sell‑side reaction reflects the mix of a revenue/EPS miss in the recent quarter and ongoing execution/cash concerns described above. Pre‑Market Movers: Absci

Absci Company Profile

Absci Corporation (NASDAQ: ABSI) is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company’s Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications.

The core of Absci’s offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework.